The invention related to medicine, in particular, to a method and a preparation for preventing and treating atypical osteoporosis with normal or increased bone tissue mineralization with the presence of cavities in trabecular bone sections (and conditions similar thereto involving excess mass and metabolic syndrome). The method comprises administrating a preparation comprising from 10 mg and 1000 mg of drone brood per day and from 50 IU and 100,000 IU of vitamin D or vitamins of the group D and/or active metabolites thereof per day. The preparation comprising drone brood and vitamin D or vitamins of the group D and/or active metabolites thereof can be in a powder, tablet or capsule form. The method and the preparation provide redistributing calcium in the body, reducing mineralization of soft tissues, vessels and other organs, and filling cavities in trabecular bone.

Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements.

Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements.

Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements.

A method of obtaining vitamin D from shiitake includes a) adding ethanol to shiitake powder, followed by reflux extraction, to prepare a shiitake extract; and (b) irradiating ultraviolet (UV) light to the shiitake extract prepared in step (a). When shiitake extracts are obtained and exposed to ultraviolet light under specific conditions, the content of vitamin D2 in the shiitake extracts may be increased.

A method of obtaining vitamin D from shiitake includes a) adding ethanol to shiitake powder, followed by reflux extraction, to prepare a shiitake extract; and (b) irradiating ultraviolet (UV) light to the shiitake extract prepared in step (a). When shiitake extracts are obtained and exposed to ultraviolet light under specific conditions, the content of vitamin D2 in the shiitake extracts may be increased.

The use of 1-alpha-hydroxyvitamin D5 or related compounds as prophylactic or therapeutic agents for SARS-CoV-2 (Covid-19 virus) and related infections. The compounds may be administered orally, by inhalation, nasal spray, eye drops, or by injection. The compounds may be administered to persons who are unwilling, unable or adverse to be vaccinated. The compounds also may be administered to immunocompromised persons for whom vaccination may not provide adequate protection from infection.

The use of 1-alpha-hydroxyvitamin D5 or related compounds as prophylactic or therapeutic agents for SARS-CoV-2 (Covid-19 virus) and related infections. The compounds may be administered orally, by inhalation, nasal spray, eye drops, or by injection. The compounds may be administered to persons who are unwilling, unable or adverse to be vaccinated. The compounds also may be administered to immunocompromised persons for whom vaccination may not provide adequate protection from infection.

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.